Minivelle® Available by Prescription Nationwide for Prevention of Postmenopausal Osteoporosis
Noven Pharmaceuticals, Inc. announced that the new 0.025 mg/day dosage strength for Minivelle® (estradiol transdermal system) is now available by prescription nationwide for only the prevention of postmenopausal osteoporosis. The FDA initially approved Minivelle in October 2012 to treat moderate to severe vasomotor symptoms (VMS) due to menopause, commonly known as hot flashes. In September 2014, the FDA approved a new indication for prevention of postmenopausal osteoporosis for all doses of Minivelle. The new 0.025 mg/day low dose was approved for this indication only.